The 62 references in paper A. Ariev L., N. Ovsyannikova A., G. Arieva T., А. АРЬЕВ Л., Н. ОВСЯННИКОВА А., Г. АРЬЕВА Т. (2011) “ФАКТОРЫ РИСКА РАЗВИТИЯ И ПРОГРЕССИРОВАНИЯ ПАТОЛОГИИ ПОЧЕК, СЕРДЕЧНО!СОСУДИСТОЙ И ЦЕРЕБРОВАСКУЛЯРНОЙ СИСТЕМ ЕДИНЫ (ВЗГЛЯД ГЕРИАТРА) // THE RISK FACTORS OF DEVELOPMENT AND PROGRESSING OF THE PATHOLOGY OF KIDNEYS, CARDIOVASCULAR AND CEREBROVASCULAR SYSTEMS ARE UNIFORM (VIEWS OF THE GERIATRITION)” / spz:neicon:nefr:y:2011:i:1:p:76-83

1
Мухин НА, Моисеев ВС. Пропедевтика внутренних болезней. ГЭОТАР-Медиа, М., 2009
(check this in PDF content)
2
Симоненко ВБ, Широков ЕА. Превентивная кардио\r неврология. Фолиант, СПб., 2008
(check this in PDF content)
3
Волженин ВЕ, Шоломов ИИ, Волженина ЖН. Анализ предикторов снижения мозгового кровотока при кардиальных и цереброваскулярных заболеваниях. В: Кардионевро\r логия: Тр. I Нац. Конгр. М., 2008; 87–93
(check this in PDF content)
4
Смирнов АВ, Каюков ИГ, Добронравов ВА. Концепция факторов риска в нефрологии: вопросы профилактики и лечения хронической болезни почек. Нефрология 2008; 12(1): 7–13
(check this in PDF content)
5
Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study). Lancet 2004; 364(9438): 937–952
(check this in PDF content)
6
Kannel WB, Wolf PA, McGee DL et al. Systolic blood pressure, arterial rigidity, and risk of stroke: The Framingham study. JAMA 1981; 245(12): 1225–1229
(check this in PDF content)
7
Шилов ЕМ. Хроническая болезнь почек. Тер арх 2007; 79(6): 75–78
(check this in PDF content)
8
Haroun MK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003; 14(11): 2934–2941
(check this in PDF content)
9
Ruilope LM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12(2): 218–225
(check this in PDF content)
10
Mann JF. Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors. Presse Mйd 2005; 34(18): 1303–1308
(check this in PDF content)
11
Тюкина АК, Игонин ВА, Иванов ВА, Фисун АЯ. Сосудодвигательная и нитроксидпродуцирующая функции эндотелия при ишемической болезни почек у больных с артериальной гипертензией. Воен\rмед журн 2008; 329(2): 63
(check this in PDF content)
12
Segura J, Campo C, Ruilope LM. Chronic kidney disease and global cardiovascular risk in essential hypertension. Minerva Med 2004; 95(5): 375–383
(check this in PDF content)
13
Кузьмин ОБ, Пугаева МО, Чуб СВ. Легкая дисфункция почек у больных с эссенциальной гипертонией: клинические проявления и лекарственная терапия. Нефрология 2004; 8(3): 15–21
(check this in PDF content)
14
Бехтерева НА. Комплексная оценка состояния гемо\r стаза, центральной и мозговой гемодинамики у больных гипертонической болезнью. Автореф. дис. ... д-ра мед. наук. Ростов. гос. мед. ун-т, Ростов н/Д, 2003
(check this in PDF content)
15
Варакин ЮЯ, Горностаева ГВ, Кравченко МА, Ощепкова ЕВ. Низок ли риск инсульта при «мягкой» артериальной гипертонии? В: Кардионеврология: Тр. I Нац. Конгр. М., 2008; 171–199
(check this in PDF content)
16
Скворцова ВИ, Соколов КВ, Шамалов НА. Артериальная гипертония и цереброваскулярные заболевания: Обзор. Журн. неврол и психиатр 2006; 106(11): 57–65
(check this in PDF content)
17
Hulley SB, Furberg CD, Gurland B et al. Systolic Hypertension in the Elderly Program (SHEP): antihypertensive efficacy of chlorthalidone. Am J Cardiol 1985; 56(15): 913–920
(check this in PDF content)
18
McMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Pt. 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335(8692): 765–774
(check this in PDF content)
19
McBride PE, Underbakke G. Dyslipidemia. In: Taylor R .et al., eds. Family medicine: principles and practice, 4th ed. NY, 1994; 494–501
(check this in PDF content)
20
Глыбочко ПВ, Востриков ЯШ, Свистунов АА. Гомеос\r таз и функции жизненно важных органов у больных мульти\r фокальным атеросклерозом в процессе комплексного лечения. Приволж. кн. изд-во, Саратов, 2003
(check this in PDF content)
21
21Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58(1): 293–301
(check this in PDF content)
22
Смирнов АВ. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 6(2): 8–14
(check this in PDF content)
23
Смирнов АВ, Есаян АМ, Каюков ИГ, Кучер АГ. Хрони\r ческая болезнь почек: определение, классификация, диаг\r ностика. Изд-во СПбГМУ, СПб., 2007
(check this in PDF content)
24
Панина ИЮ, Румянцев АШ, Меншутина МА и др. Особенности функции эндотелия при хронической болезни почек: Обзор литературы и собственные данные. Нефрология 2007;11(4): 28–46
(check this in PDF content)
25
Yang X, So W Y, Ma RC et al. Thresholds of risk factors for ischemic stroke in type 2 diabetic patients with and without albuminuria: a non-linear approach. Clin Neurol Neurosurg 2008; 110(7): 701–709
(check this in PDF content)
26
Millican C, McDowell F, Easton JD. Stroke. Lea & Febiger, Philadelphia, 1987
(check this in PDF content)
27
Добронравов ВА. Эпидемиология диабетической нефропатии: общие и региональные проблемы. Нефроло\r гия 2002; 6(1): 16–22
(check this in PDF content)
28
Hsu CY, McCulloch CE, Iribarren C et al. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006: 144(1): 21–28
(check this in PDF content)
29
Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6 year study. Diabetes Res Clin Pract 1995; 28(2): 103–117
(check this in PDF content)
30
Оганов РГ. Сочетание компонентов метаболического синдрома связано с высоким риском атеросклеротических заболеваний. Кардиоваскулярная тер и профилактика 2004; (1): 56–59
(check this in PDF content)
31
Heffron WA. Obesity. In: Taylor R et al., eds. Family medicine: principles and practice 4th ed. NY, 1994; 424– 42932Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Int Med 2004; 140(3): 167–174
(check this in PDF content)
32
Chen J, Muntner P, Hamm LL et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Int Med 2004; 140(3): 167–174
(check this in PDF content)
33
Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69(2): 369–374
(check this in PDF content)
34
Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71(3): 260–265
(check this in PDF content)
35
Смирнов АВ, Петрищев НН, Панина ИЮ. и др. Скорость клубочковой фильтрации – показатель функционального состояния эндотелия на ранних стадиях развития хронической болезни почек. Тер арх 2007; 79(6): 25–30
(check this in PDF content)
36
Смирнов АВ, Добронравов ВА, Голубев РВ. и др. Распространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек. Нефрология 2005; 9(2): 48–52
(check this in PDF content)
37
Stuveling EM, Bakker SJ, Hillege HL et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20(3): 497–508
(check this in PDF content)
38
Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S et al. Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999; 19(8): 1992–1997
(check this in PDF content)
39
McQueen MJ, Lonn E, Gerstein HC et al. The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences. Scand J Clin Lab Invest (Suppl) 2005; 240: 143– 156
(check this in PDF content)
40
Wada M, Nagasawa H, Kurita K et al. Microalbuminuria is a risk factor for cerebral small vessel disease in communitybased elderly subjects. J Neurol Sci 2007; 255(1–2): 27–34
(check this in PDF content)
41
Hojs Fabjan T, Hojs R, Tetickovic E, Pecovnik Balon B. Ischaemic stroke — impact of renal dysfunction on in-hospital mortality. Eur J Neurol 2007; 14(12): 1351–1356
(check this in PDF content)
42
Szczudlik A, Turaj W, Sіowik A, Strojny J. Microalbuminuria and hyperthermia independently predict long-term mortality in acute ischemic stroke patients. Acta Neurol Scand 2003; 107(2): 96–101
(check this in PDF content)
43
Olsen MH, Wachtell K, Ibsen H et al. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study. J Hypertens 2006; 24(4): 775–781
(check this in PDF content)
44
Тугушева ФА, Зубина ИМ, Митрофанова ОВ. Оксидативный стресс и хроническая болезнь почек: Обзор лит. Нефрология 2007; 11(3): 29–47
(check this in PDF content)
45
Horl WH, Cohen JJ, Harrington JT et al. Atherosclerosis and uremic retention solutes. Kidney Int 2004; 66(4): 1719– 1731
(check this in PDF content)
46
Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Seminars Nephrol 2004; 24(5): 469–473
(check this in PDF content)
47
Zalba G, Fortuсo A, Dнez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant 2006; 21(10): 2686–2690
(check this in PDF content)
48
Pai JK, Pischon T, Ma J et al. Inflammatory markers and the risk of coronary heart disease in men and women. New Engl J Med 2004; 351(25): 2599–2610
(check this in PDF content)
49
Owen WF, Lowrie EG. C reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54(2): 627–636
(check this in PDF content)
50
Menon V, Greene T, Wang X et al. C reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int 2005; 68(2): 766–772
(check this in PDF content)
51
Bemeur C, Sainte-Marie L, Montgomery J. Increased oxidative stress during hyperglycemic cerebral ischemia. Neurochem Int 2007; 50(7–8): 890–904
(check this in PDF content)
52
Wong CH, Crack PJ. Modulation of neuro-inflammation and vascular response by oxidative stress following cerebral ischemia-reperfusion injury. Curr Med Chem 2008; 15(1): 1–14
(check this in PDF content)
53
Vollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74(1): 130–136
(check this in PDF content)
54
Черкас ЮВ, Денисенко АД. Определение содержания гомоцистеина в плазме крови человека методом изократической обращенно-фазовой жидкостной хроматографии. Клин лаб диагностика 2001; (5): 35–37
(check this in PDF content)
55
Hoogeveen EK, Kostense PJ, Jakobs C et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5 year follow-up of the Hoorn Study. Circulation 2000; 101 (13): 1506–1511
(check this in PDF content)
56
Mallamaci F, Zoccali C, Tripepi G et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int 2002; 61(2): 609–614
(check this in PDF content)
57
Zhloba AA, Blashko EL. Liquid chromatographic determination of total homocysteine in blood plasma with photometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004; 800 (1-2): 275–280
(check this in PDF content)
58
Bostom AG, Shemin D, Verhoef P et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients: A prospective study. Arterioscler Thromb Vasc Biol 1997; 17(11): 2554–2558
(check this in PDF content)
59
Болдырев АА. Новые направления в исследовании гипергомоцистеинемии как фактора риска сердечно-сосудистых и нейродегенеративных заболеваний. В: Кардио\r неврология: Тр. I Нац. Конгр. М., 2008; 110–115
(check this in PDF content)
60
Orth SR, Hallan SI. Smoking: a risk factor for progression of chronic kidney disease and for cardiovascular morbidity and mortality in renal patients: absence of evidence or evidence of absence? Clin J Am Soc Nephrol 2008; 3(1): 226–236
(check this in PDF content)
61
Warmoth L, Regalado MM, Simoni J et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330(3): 111–119
(check this in PDF content)
62
Смирнов АВ, Добронравов ВА, Каюков ИГ и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология 2006; 10(1): 7–13 Ïîñòóïèëà â ðåäàêöèþ 28.01.2011 ã. Ïðèíÿòà â ïå÷àòü 09.02.2011 ã.
(check this in PDF content)